C
Climb Bio
Rethinking treatment for nervous system disorders, empowering patients to live on their own terms
About Climb Bio
Eliem Therapeutics, Inc. is a clinical-stage biotechnology company headquartered in Seattle and Cambridge, United Kingdom. The company is dedicated to developing innovative therapies for chronic pain and neuropsychiatric conditions. Eliem operates in the life sciences sector, primarily targeting patients who suffer from debilitating conditions that lack effective treatment options. The company's business model revolves around extensive research and development (R&D) to create novel pharmaceutical solutions. Eliem generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary drugs. The company recently announced an agreement to acquire Tenet Medicines, Inc., and a concurrent $120 million private placement of common stock with a syndicate of institutional life science investors. This acquisition aims to advance TNT119, an anti-CD19 antibody designed for treating a broad range of autoimmune diseases.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 41
- Open positions
- None listed
- Dealroom signal
- 94.1/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotechnology, Neurology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Investment activity
- 1 company, latest Apr 2024
- Capital deployed
- —
- Preferred round
- ACQUISITION
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| PRIVATE PLACEMENT NON VCOther financing | Apr 2026 | $110M | — | RA Capital Management · Driehaus Capital Management · Woodline Partners · Affinity Asset Advisors | ↗ |
| PRIVATE PLACEMENT VCOther financing | Apr 2024 | $120M | — | Janus Henderson Investors · Samsara BioCapital · Deep Track Capital · RA Capital Management | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Climb Bio is 1.9K monthly website visits, up 72.7% over the last three months. Climb Bio's team grew 17.1% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Climb Bio in the Wellesley ecosystem
The Climb Bio office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A6 investors entered at this stage
RA Capital Management
Intermediate Capital Group
Access Biotechnology
LifeArc
Acorn Bioventures
Samlyn Capital
Other known investors14 additional known investors
ADAR1 Capital Management
Affinity Asset Advisors
Ally Bridge Group
Boxer Capital
Cormorant Asset Management
Deep Track Capital
Driehaus Capital Management
Great Point PartnersJanus Henderson Investors
Pontifax AgTech
Redmile Group
Samsara BioCapital
Sirenia Capital Management
Woodline Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Climb Bio on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Climb Bio’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








